Clark Wealth Partners’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.18K Buy
4
+1
+33% +$264 ﹤0.01% 782
2026
Q2
$681 Hold
3
– – ﹤0.01% 515
2026
Q1
$518 Hold
3
– – ﹤0.01% 561
2025
Q4
$598 Hold
3
– – ﹤0.01% 521
2025
Q3
$598 Hold
3
– – ﹤0.01% 521
2025
Q2
$455 Buy
+3
New +$400 ﹤0.01% 492

Other funds holding CRL

Clark Wealth Partners's CRL Position: Q3 2026 in Review

Clark Wealth Partners increased its Charles River Laboratories (CRL) stake by 33% in Q3 2026, buying an estimated $264 and bringing the position to 4 shares worth $1.18K. The position accounts for ﹤0.01% of the portfolio, ranked #782.

Clark Wealth Partners first reported a position in CRL in Q2 2025 and has held it in 6 quarters since. 642 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Clark Wealth Partners held 4 shares of Charles River Laboratories worth $1.18K as of Q3 2026.
  • Clark Wealth Partners bought 1 Charles River Laboratories share in Q3 2026, an estimated $264.
  • Charles River Laboratories made up ﹤0.01% of Clark Wealth Partners's portfolio in Q3 2026, its #782 holding.
  • Clark Wealth Partners first reported a position in Charles River Laboratories in Q2 2025 and has held it in 6 quarters since.
  • 642 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Clark Wealth Partners's 13F filing for Q3 2026, filed 19 Oct 2026.